Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Li, Song ^a   Wang, Baolu ^a   Xu, Yan ^b   Zhang, Junjie ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BROMO 3 HYDROXY 4 (PALMITOYLOXY)BUTYLPHOSPHONATE; 4 (TETRADECANOYLAMINO) BENZYL PHOSPHONIC ACID DISODIUM SALT; ANTINEOPLASTIC AGENT; AUTOTAXIN; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 7; LYSOPHOSPHATIDIC ACID; S 32826; SMALL INTERFERING RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG; (4 (TETRADECANOYLAMINO)BENZYL)PHOSPHONIC ACID; (4-(TETRADECANOYLAMINO)BENZYL)PHOSPHONIC ACID; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; ANILIDE; BRP LPA; BRP-LPA; ENPP2 PROTEIN, HUMAN; HDAC7 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INORGANIC PYROPHOSPHATASE; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHOLIPID; MESSENGER RNA; MULTIENZYME COMPLEX; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHONIC ACID DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; ACETYLATION; CELL PROTECTION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ACETYLATION; ANILIDES; APOPTOSIS; CELL LINE, TUMOR; CYTOPROTECTION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LYSOPHOSPHOLIPIDS; MULTIENZYME COMPLEXES; PHOSPHODIESTERASE I; PHOSPHONIC ACIDS; PHOSPHORIC DIESTER HYDROLASES; PROMOTER REGIONS, GENETIC; PYROPHOSPHATASES; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 79751532169     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-18     Document Type: Article

References (49)

1. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992, 267:2524-2529.
2. Jansen S, Stefan C, Creemers JW, Waelkens E, Van Eynde A, Stalmans W, Bollen M. Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J Cell Sci 2005, 118:3081-3089. 10.1242/jcs.02438, 15985467.
3. Boutin JA, Ferry G. Autotaxin. Cell Mol Life Sci 2009, 66:3009-3021. 10.1007/s00018-009-0056-9, 19506801.
4. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002, 158:227-233. 10.1083/jcb.200204026, 2173129, 12119361.
5. Jansen S, Andries M, Vekemans K, Vanbilloen H, Verbruggen A, Bollen M. Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 2009, 284:216-221. 10.1016/j.canlet.2009.04.029, 19482419.
6. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006, 26:5015-5022. 10.1128/MCB.02419-05, 1489177, 16782887.
7. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006, 281:25822-25830. 10.1074/jbc.M605142200, 16829511.
8. Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004, 26:870-881. 10.1002/bies.20081, 15273989.
9. Noguchi K, Herr D, Mutoh T, Chun J. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 2009, 9:15-23. 10.1016/j.coph.2008.11.010, 19119080.
10. Luquain C, Sciorra VA, Morris AJ. Lysophosphatidic acid signaling: how a small lipid does big things. Trends Biochem Sci 2003, 28:377-383. 10.1016/S0968-0004(03)00139-7, 12878005.
11. Georas SN. Lysophosphatidic acid and autotaxin: emerging roles in innate and adaptive immunity. Immunol Res 2009, 45:229-238.
12. Fotopoulou S, Oikonomou N, Grigorieva E, Nikitopoulou I, Paparountas T, Thanassopoulou A, Zhao Z, Xu Y, Kontoyiannis DL, Remboutsika E, Aidinis V. ATX expression and LPA signalling are vital for the development of the nervous system. Dev Bio 2010, 399:451-64l.
13. Ptaszynska MM, Pendrak ML, Stracke ML, Roberts DD. Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res 2010, 8:309-321. 10.1158/1541-7786.MCR-09-0288, 20197381.
14. Im E, Motiejunaite R, Aranda J, Park EY, Federico L, Kim TI, Clair T, Stracke ML, Smyth S, Kazlauskas A. PLC{gamma} activation drives increased production of autotaxin in endothelial cells and LPA-dependent regression. Mol Cell Biol 2010, 30:2401-2410. 10.1128/MCB.01275-09, 2863716, 20231358.
15. van Meeteren LA, Moolenaar WH. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 2007, 46:145-160. 10.1016/j.plipres.2007.02.001, 17459484.
16. Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 2000, 19:241-247. 10.1038/sj.onc.1203263, 10645002.
17. Chen M, O'Connor KL. Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 2005, 24:5125-5130. 10.1038/sj.onc.1208729, 15897878.
18. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009, 15:539-550. 10.1016/j.ccr.2009.03.027, 19477432.
19. Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, Kaye SB, Richardson A. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal 2010, 22:926-935. 10.1016/j.cellsig.2010.01.017, 20100569.
20. Samadi N, Gaetano C, Goping IS, Brindley DN. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 2009, 28:1028-1039. 10.1038/onc.2008.442, 19079345.
21. North EJ, Howard AL, Wanjala IW, Pham TC, Baker DL, Parrill AL. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. J Med Chem 2010, 53:3095-3105. 10.1021/jm901718z, 20349977.
22. Wu JM, Xu Y, Skill NJ, Sheng H, Zhao Z, Yu M, Saxena R, Maluccio MA. Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol Cancer 2010, 9:71. 10.1186/1476-4598-9-71, 2867819, 20356387.
23. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T, Arai H. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 2006, 281:17492-17500. 10.1074/jbc.M601803200, 16627485.
24. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets?. Cancer Lett 2009, 277:8-21. 10.1016/j.canlet.2008.08.016, 18824292.
25. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009, 107:600-608. 10.1002/jcb.22185, 2766855, 19459166.
26. Kim JK, Samaranayake M, Pradhan S. Epigenetic mechanisms in mammals. Cell Mol Life Sci 2009, 66:596-612. 10.1007/s00018-008-8432-4, 2780668, 18985277.
27. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009, 15:3958-3969. 10.1158/1078-0432.CCR-08-2785, 19509172.
28. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784. 10.1038/nrd2133, 16955068.
29. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468. 10.1200/JCO.2009.22.1291, 19826124.
30. Wilson AJ, Chueh AC, Togel L, Corner GA, Ahmed N, Goel S, Byun DS, Nasser S, Houston MA, Jhawer M, Smarrt HJ, Murray LB, Nicholas C, Heerdt BG, Arango D, Augenlicht LH, Mariadason JM. Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 2010, 70:609-620. 10.1158/0008-5472.CAN-09-2327, 2939837, 20068171.
31. Prestwich GD, Gajewiak J, Zhang H, Xu X, Yang G, Serban M. Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta 2008, 1781:588-594. 2597578, 18454946.
32. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, Fells JI, Perygin D, Parrill AL, Tigyi G, Prestwich GD. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 2009, 69:5441-5449. 10.1158/0008-5472.CAN-09-0302, 19509223.
33. Xu X, Yang G, Zhang H, Prestwich GD. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Prostaglandins Other Lipid Mediat 2009, 89:140-146. 10.1016/j.prostaglandins.2009.07.006, 2756011, 19682598.
34. Ferry G, Moulharat N, Pradere JP, Desos P, Try A, Genton A, Giganti A, Beucher-Gaudin M, Lonchampt M, Bertrand M, Saulnier Blache JS, Tucker GC, Cordi A, Boutin JA. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther 2008, 327:809-819. 10.1124/jpet.108.141911, 18755937.
35. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 2001, 276:35826-35835. 10.1074/jbc.M104935200, 11466315.
36. Ptaszynska MM, Pendrak ML, Bandle RW, Stracke ML, Roberts DD. Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol Cancer Res 2008, 6:352-363. 10.1158/1541-7786.MCR-07-0143, 2442564, 18337445.
37. Bachner D, Ahrens M, Schroder D, Hoffmann A, Lauber J, Betat N, Steinert P, Flohe L, Gross G. Bmp-2 downstream targets in mesenchymal development identified by subtractive cloning from recombinant mesenchymal progenitors (C3H10T1/2). Dev Dyn 1998, 213:398-411. 10.1002/(SICI)1097-0177(199812)213:4<398::AID-AJA5>3.0.CO;2-T, 9853961.
38. Wang S, Li X, Parra M, Verdin E, Bassel-Duby R, Olson EN. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci USA 2008, 105:7738-7743. 10.1073/pnas.0802857105, 2409381, 18509061.
39. Jensen ED, Gopalakrishnan R, Westendorf JJ. Bone morphogenic protein 2 activates protein kinase D to regulate histone deacetylase 7 localization and repression of Runx2. J Biol Chem 2009, 284:2225-2234. 10.1074/jbc.M800586200, 2629084, 19029091.
40. Zhong S, Goto H, Inagaki M, Dong Z. Phosphorylation at serine 28 and acetylation at lysine 9 of histone H3 induced by trichostatin A. Oncogene 2003, 22:5291-5297. 10.1038/sj.onc.1206507, 12917630.
41. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202. 10.1038/35106079, 11902574.
42. Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007, 13:7237-7242. 10.1158/1078-0432.CCR-07-2114, 18094401.
43. East JE, Kennedy AJ, Tomsig JL, De Leon AR, Lynch KR, Macdonald TL. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX). Bioorg Med Chem Lett 2010, 20:7132-7136. 10.1016/j.bmcl.2010.09.030, 20951039.
44. Albers HM, van Meeteren LA, Egan DA, van Tilburg EW, Moolenaar WH, Ovaa H. Discovery and optimization of boronic acid based inhibitors of autotaxin. J Med Chem 53:4958-4967. 10.1021/jm1005012, 20536182.
45. Cavalli S, Houben AJ, Albers HM, van Tilburg EW, de Ru A, Aoki J, van Veelen P, Moolenaar WH, Ovaa H. Development of an Activity-Based Probe for Autotaxin. Chembiochem 2010, 11:2311-2317. 10.1002/cbic.201000349, 20941725.
46. Li X, Song S, Liu Y, Ko SH, Kao HY. Phosphorylation of the histone deacetylase 7 modulates its stability and association with 14-3-3 proteins. J Biol Chem 2004, 279:34201-34208. 10.1074/jbc.M405179200, 15166223.
47. Zhang X, Ozawa Y, Lee H, Wen YD, Tan TH, Wadzinski BE, Seto E. Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev 2005, 19:827-839. 10.1101/gad.1286005, 1074320, 15805470.
48. Li S, Zhang J. Lipopolysaccharide induces autotaxin expression in human monocytic THP-1 cells. Biochem Biophys Res Commun 2009, 378:264-268. 10.1016/j.bbrc.2008.11.047, 19027716.
49. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL, Augenlicht LH. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003, 63:8791-8812.